TL;DR
- 1.Semax drives BDNF and dopamine upward. It sharpens cognition and motivation. It is not an anxiolytic.
- 2.Selank matched a benzodiazepine for anxiety relief in a clinical trial, with zero sedation, tolerance, or withdrawal.
- 3.The wrong choice can make things worse. Semax on top of unresolved anxiety typically amplifies it. Start with the problem, not the peptide.
- 4.Your COMT Val158Met variant is the clearest predictor of which one you need. Slow-COMT individuals should default to Selank. Fast-COMT individuals get more from Semax.
- 5.Both peptides were removed from the FDA restricted compounding list in April 2026. A formal PCAC review is scheduled for July 23-24, 2026.
Semax can elevate BDNF expression in hippocampal neurons within hours of a single dose. Selank matched a benzodiazepine for anxiety relief in a published clinical trial, with none of the sedation or withdrawal. These peptides share a category and an origin, but they solve completely different problems. Using the wrong one does not just fail to help. For some genotypes, it makes things measurably worse.
A 2025 study in Acta Naturae (Radchenko et al., PMID 41479572) found that intranasal Semax reduced cortical amyloid plaques 2.8-fold in a transgenic Alzheimer's mouse model after one month of every-other-day dosing. The same protocol restored spatial memory and novel object recognition to near-control levels. This is a peptide that has been in Russian hospitals for stroke treatment since the 1990s. The amyloid-clearing mechanism was not discovered until 2025.
The confusion is understandable. Both peptides were developed in Russia in the 1980s and 1990s. Both are administered intranasally. Both affect brain chemistry within minutes of dosing. Both clear your plasma in under 5 minutes. Their downstream effects, however, last for hours, and the nature of those effects could not be more different. Semax is a stimulating, trophic peptide: it pushes neuroplasticity upward by driving BDNF and NGF gene expression, and facilitates dopamine in the prefrontal cortex. Selank is a calming, homeostatic peptide: it extends the life of your brain's own endogenous opioid peptides by blocking the enzyme that degrades them, and recalibrates GABA-A receptor sensitivity without forcing it on.
The simplest framing: Semax sharpens. Selank calms. Everything else follows from that.
Think of your brain's anxiety response as a security alarm wired to go off too easily. Benzodiazepines cut the power to the alarm entirely. That works fast, but the building has no security until the power comes back, and when it does the alarm is extra sensitive. Selank recalibrates the alarm's threshold so it only fires for real threats. Semax does something different: it repairs the building's wiring so it functions better under normal conditions. Different tools for different jobs. Using Semax on an overactive alarm is like upgrading the wiring on a building that is already on fire.
Why Semax and Selank feel nothing alike
Most people who have used both describe a clear subjective contrast. Semax users report increased clarity, drive, and mental stamina, similar to a well-calibrated stimulant but without jitteriness or crash. Selank users report a quiet settling of background anxiety, improved emotional resilience, and often a mild secondary sharpening of cognition once anxiety stops interfering. These descriptions match the underlying pharmacology precisely.
Derived from adrenocorticotropic hormone (ACTH), Semax activates the melanocortin receptor pathway and the CREB transcription factor, directly driving BDNF and NGF gene expression within hours. It also facilitates dopamine and serotonin turnover in the prefrontal cortex and striatum. A 2025 paper in Bioinorganic Chemistry and Applications (PMID 40496623) identified a third unexpected mechanism: the His-Phe sequence in Semax forms an ATCUN copper-binding motif that strips copper from amyloid-beta complexes. And a 2025 paper in the British Journal of Pharmacology (Liu et al., PMID 40692165) found Semax activates the mu-opioid receptor gene Oprm1, a mechanism nobody predicted. Best matched to: cognitive dulling, motivation deficit, low-dopamine brain fog, post-stroke recovery, neuroprotection goals.
Derived from tuftsin, an endogenous immune peptide, Selank's primary mechanism is enkephalinase inhibition. It blocks the enzyme that degrades your brain's natural endogenous opioid peptides (enkephalins), extending the life of these calming signals after your brain produces them. A 2018 study in Protein and Peptide Letters (Vyunova et al., PMID 30255741) confirmed Selank also acts as a subtype-selective allosteric modulator of GABA-A receptors, binding at a site distinct from benzodiazepines and modulating receptor sensitivity rather than forcing activation. A 2020 study in Current Reviews in Clinical and Experimental Pharmacology (PMID 32621722) documented that Selank normalizes IL-6, TNF-alpha, IL-1beta, and TGF-beta1 under chronic psychological stress. Best matched to: generalized anxiety, stress reactivity, rumination, sleep-onset anxiety, anxiety amplified by inflammation.
There is one mechanism both peptides share that almost no Western article mentions correctly. A study in the Russian Journal of Bioorganic Chemistry (Kost et al., PMID 11443939) found that Semax and Selank both inhibit enkephalin-degrading enzymes in human serum, with Semax at an IC50 of approximately 10 micromolar and Selank at approximately 20 micromolar. For comparison, bacitracin, the standard research tool for preserving enkephalins in lab assays, requires approximately 10 millimolar to achieve the same effect. Both peptides outperform bacitracin by roughly 1,000-fold. The implication: every dose of Semax or Selank also amplifies the life of your brain's own natural calming peptides. No receptor binding. No tolerance mechanism. No withdrawal.
What the 2025 Semax studies actually found
Semax has been used clinically in Russia since the 1990s, primarily for stroke and ischemic brain injury. The 2025 literature added three findings that substantially update the mechanistic picture.
The spinal cord paper is the most surprising. A 2025 study in the British Journal of Pharmacology (Liu et al., PMID 40692165) found that Semax promotes motor recovery after T9-T10 spinal cord injury by targeting the mu-opioid receptor gene Oprm1, which then upregulates the deubiquitinase USP18 and reduces inflammatory pyroptosis (a particularly destructive form of inflammatory cell death). No one was looking for this. Semax was understood as acting through ACTH-like and BDNF pathways. The opioid receptor pathway is entirely separate from both.
Semax upregulated USP18 and deubiquitinated FTO via the mu-opioid receptor, reducing pyroptosis and significantly improving hindlimb motor function scores after spinal cord injury. This mechanism does not overlap with any previously identified Semax pathway.
Liu et al., British Journal of Pharmacology, 2025 (PMID 40692165)
The amyloid finding is what matters most for long-term neuroprotection users. The 2025 Acta Naturae study (Radchenko et al., PMID 41479572) used the APP/PS1 transgenic mouse, the standard Alzheimer's preclinical model, and found that one month of every-other-day intranasal Semax reduced cortical plaques 2.8-fold and hippocampal plaques 2.6-fold compared to untreated controls, with memory test normalization. The 2025 Bioinorganic Chemistry and Applications paper (PMID 40496623) identified the mechanism: the ATCUN copper-binding motif in Semax's structure strips copper from amyloid-beta, preventing the copper-mediated oxidative damage that drives plaque formation. Two anti-amyloid mechanisms in one peptide. Neither exists in any currently approved Alzheimer's drug.
For the cognitive performance use case, a 2021 study in the International Journal of Molecular Sciences (Sudarkina et al., PMC8226508) found that Semax suppressed inflammatory JNK signaling approximately 1.5-fold and boosted pro-survival CREB phosphorylation in cortical tissue after experimental stroke. The same CREB activation that drives neuroprotection is the mechanism behind Semax's cognitive effects in healthy users. Protection and enhancement share one molecular pathway. For a deeper look at the brain fog applications specifically, see the brain fog peptide guide, which covers how BDNF genetics predict your response.
What Selank actually does for anxiety (and why it is not just a GABA peptide)
Most articles classify Selank as a GABAergic peptide and stop there. The GABA modulation is real, but the mechanism is not what the shorthand implies. The Vyunova et al. 2018 study confirmed that Selank does not activate GABA receptors directly. It binds at an allosteric site distinct from benzodiazepines and modulates receptor sensitivity rather than forcing activation. This is why Selank produces anxiolysis without sedation and without the receptor desensitization that drives benzodiazepine tolerance. It tunes the system rather than overriding it.
The enkephalinase inhibition is the mechanism almost no Western article explains correctly. Enkephalinase (also called neutral endopeptidase or neprilysin) is the enzyme that breaks down your brain's endogenous opioid peptides after they are released. These peptides, called enkephalins, are part of your natural anxiety regulation system. Selank slows their degradation, extending their activity window after your brain produces them. This is not a pharmacological signal from outside. It is your own calming system, running longer. The effect users describe as "feeling like yourself on a good day" is not metaphorical. It is mechanistically accurate.
The clinical evidence is summarized in detail in the Selank anxiety guide: a head-to-head trial against medazepam (the benzodiazepine used as the standard anxiolytic reference in Russian psychiatry) enrolled 62 patients with generalized anxiety disorder or neurasthenia and found equivalent anxiolytic efficacy. The Selank group showed additional antiasthenic effects (patients felt more alert, not sedated) and zero withdrawal on discontinuation. Forty percent of patients reached sub-clinical Hamilton Anxiety Rating Scale scores within three days. The remaining sixty percent reached similar final scores by day fourteen. Both groups landed at remission. The difference was only timing.
Semax vs Selank: direct comparison
| Feature | Semax | Selank |
|---|---|---|
| Primary effect | Cognitive activation, neuroplasticity, motivation | Anxiety reduction, emotional regulation, stress resilience |
| Main mechanism | BDNF/NGF via CREB; dopamine facilitation; copper chelation; mu-opioid receptor modulation | Enkephalinase inhibition; GABA-A allosteric modulation; cytokine normalization |
| Plasma half-life | ~2 to 5 minutes | ~2 to 3 minutes |
| Effect duration | Hours; BDNF protein elevation may persist 24+ hours after clearance | ~3 to 5 hours per dose |
| Intranasal bioavailability | High (olfactory pathway CNS access) | ~92.8% (among the highest of any peptide via any route) |
| Sedation | None (mild stimulant profile) | None |
| Anxiogenic risk | Yes, in slow-COMT individuals or at high doses | None documented |
| Russian approval | Stroke treatment, since 1990s | GAD and neurasthenia, since 2009 |
| US compounding status (June 2026) | Off Category 2 list since April 2026; PCAC review scheduled July 23-24, 2026 | Off Category 2 list since April 2026; PCAC review scheduled July 23-24, 2026 |
| Best genetic match | BDNF Met allele; fast-COMT Val/Val | GABRA2 risk variants; slow-COMT Met/Met; IL-6 inflammatory variants |
How to choose based on your actual symptoms
The choice almost always comes down to one question: is your cognitive problem driven by low neuroplasticity and dopamine tone, or by anxiety that is interfering with cognition from upstream? These are different problems. A stimulating nootropic applied to anxiety-driven cognitive impairment will typically worsen the anxiety and produce no lasting cognitive improvement. An anxiolytic applied to genuine dopamine deficit will calm you without resolving the fog.
| Your primary symptom | What it suggests | Starting point |
|---|---|---|
| Difficulty focusing, low motivation, mental fatigue, no anxiety | Low dopamine or BDNF tone in prefrontal cortex | Semax |
| Persistent background anxiety, rumination, stress reactivity | GABAergic dysregulation or enkephalin depletion | Selank |
| Brain fog that worsens when anxious or stressed | Anxiety-driven cognitive impairment (the majority of cases) | Selank first; add Semax only if fog persists after anxiety resolves |
| Brain fog with no anxiety, worse after exertion or viral illness | Neuroinflammation or post-viral BDNF deficit | Semax (consider BPC-157 if gut symptoms coexist) |
| High cognitive demands with no significant anxiety | Performance optimization, not deficit correction | Semax |
| Social anxiety plus low energy and motivation | Mixed: anxiety plus possible low dopamine | Selank first; re-evaluate at 2 to 4 weeks before adding Semax |
| Post-SSRI discontinuation symptoms | Serotonin rebound plus GABAergic dysregulation | Selank only until full washout is confirmed |
One common mistake is assuming any nootropic will help anxiety-driven brain fog. If anxiety is the upstream cause of your cognitive symptoms, resolving the anxiety first with Selank typically produces faster cognitive improvement than layering a stimulating nootropic on unresolved anxiety. This is why Selank is the correct default for most people asking this question. Most people who seek out nootropic peptides have a significant anxiety component they have been working around for years without naming it. Start there.
Semax dosing: what the research supports
Semax is administered as a nasal spray. Russian clinical protocols for stroke use concentrations of 0.1% or 1%, with the 1% solution delivering approximately 500 to 1,000 micrograms per spray. For cognitive enhancement and neuroprotection outside clinical stroke settings, most protocols use 300 to 600 micrograms per day intranasally, typically split into morning and midday doses to align with peak cognitive demand windows. The BDNF upregulation Semax produces is cumulative over weeks rather than a one-dose event, which supports running it for 10 to 30 day cycles with breaks rather than indefinite daily use. Review the peptide cycling protocol guide for recommended on/off ratios.
Selank's estimated intranasal bioavailability in animal pharmacokinetic models is approximately 92.8 percent, one of the highest figures documented for any peptide via any non-injectable route. The Pro-Gly-Pro C-terminal extension that Selank shares with Semax is responsible: it slows enzymatic degradation and extends transit time through the nasal mucosa. Most subcutaneous peptide injections achieve 80 to 90 percent bioavailability. Selank matches that ceiling through the nose.
Selank dosing: what the clinical trials used
The Russian clinical trials for generalized anxiety disorder used 250 to 500 micrograms per nostril intranasally, once or twice daily. Most protocols start at 250 micrograms once daily and titrate based on response over the first week. Because Selank's effect duration is approximately 3 to 5 hours per dose, twice-daily dosing (morning and early afternoon) provides better coverage for all-day anxiety management than a single morning dose. Typical protocol length is 4 to 8 weeks, mirroring the cycle structure used in Russian clinical trials, followed by a 2-week break. Selank has not demonstrated tolerance development in published trials, but cycling it remains prudent pending longer-term human data.
Can you stack Semax and Selank together?
The AM/PM stack is used in the community and is not pharmacologically dangerous. The practical problem is diagnostic: starting both simultaneously makes it impossible to assess which one is driving improvement or causing side effects. If you start both and feel worse, you do not know which to stop. If you feel better, you cannot replicate or adjust what is working.
The correct sequence is to start with the one matched to your primary symptom, run it for 2 to 4 weeks to establish a clear response, and then add the second peptide only if needed. For people who genuinely need both, the AM/PM split works well in practice: Selank in the morning for daytime anxiety management, Semax at noon for afternoon cognitive performance. Do not dose both at the same time on the same occasion. Their overlapping BDNF activity is not a direct pharmacological risk, but the combined effect is harder to titrate when both peak simultaneously and any adverse reaction cannot be attributed to either agent specifically.
How your BDNF and COMT genes predict which one you need
Your genetics do not determine whether these peptides work. They predict which one fits your actual deficit before you run any experiment, saving you weeks of failed protocols. Two variants are particularly informative.
BDNF Val66Met (rs6265). The Met allele impairs activity-dependent BDNF secretion from hippocampal neurons. Met carriers produce approximately 30 percent less BDNF after neuronal stimulation. Since Semax works primarily by inducing BDNF gene expression via CREB, Met allele carriers have more deficit to address and potentially the most to gain from Semax. The same logic applies to Selank, which also upregulates BDNF secondarily through stress reduction. For Met carriers with mixed anxiety and cognitive symptoms, Selank may produce particularly strong overall results because it addresses both the anxiety and the downstream BDNF deficit in one protocol. A 2024 study in Frontiers in Aging Neuroscience (PMC12178939) confirmed Val66Met moderates the cognitive benefit of neuroplasticity-promoting interventions more broadly, supporting the clinical relevance of this variant for peptide selection. For more depth on this connection, see the brain fog peptide guide.
COMT Val158Met (rs4680). This variant determines how quickly your prefrontal cortex clears dopamine. Val/Val carriers (fast COMT) have lower ambient PFC dopamine and are the genotype most likely to benefit from Semax's dopaminergic facilitation. Met/Met carriers (slow COMT) already have elevated PFC dopamine. Adding Semax's dopaminergic amplification to that baseline frequently causes anxiety, over-arousal, or irritability rather than the cognitive sharpening fast-COMT users experience. For slow-COMT individuals, Selank is almost always the safer and more effective choice. Your DNA report identifies both variants in your 23andMe or AncestryDNA raw file. These are the two results that matter most before starting either peptide. Visit the Selank peptide page or the Semax peptide page for current dosing options aligned to your genetic profile.
Semax and Selank's US legal status: what actually changed in 2026
From early 2024 through April 2026, both Semax and Selank were on the FDA's Category 2 restricted bulk drug substances list, which prohibited licensed 503A compounding pharmacies from preparing either peptide. The practical effect was to cut off legal prescriber access entirely while gray-market research chemical vendors continued operating freely, with no manufacturing oversight or purity standards.
As of April 2026, both peptides were removed from the Category 2 list following the withdrawal of the nominations that had originally placed them there. The FDA's Pharmacy Compounding Advisory Committee is scheduled to review Semax and Selank at its July 23-24, 2026 meeting. If the committee recommends Category 1 placement and formal rulemaking follows, licensed compounding pharmacies will be able to prepare both peptides under physician prescription. As of June 2026, the regulatory direction is clearly toward legal access, but formal rulemaking is still pending. Both peptides remain non-scheduled by the DEA and not FDA-approved for any US indication. In Russia, both are licensed prescription drugs: Semax for stroke, Selank for generalized anxiety disorder and neurasthenia, dispensed as pharmaceutical-grade nasal sprays with verified concentration standards. Gray-market US products vary significantly in purity.
Your DNA shapes how you respond to each of these.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
What is the main difference between Semax and Selank?
Semax is a stimulating nootropic that drives BDNF and NGF expression and facilitates dopamine in the prefrontal cortex. Its primary use cases are cognitive enhancement, motivation, brain fog, and neuroprotection. Selank is a calming anxiolytic that extends the life of the brain's endogenous opioid peptides by inhibiting the enzyme that breaks them down, and modulates GABA-A receptor sensitivity. Its primary use cases are generalized anxiety, stress reactivity, and rumination. The simplest summary: Semax sharpens, Selank calms. They work through almost completely separate mechanisms.
Which is better for anxiety: Semax or Selank?
Selank, consistently and clearly. Selank matched a benzodiazepine for anxiety relief in a published clinical trial with zero sedation, tolerance, or withdrawal. Semax is not an anxiolytic and can worsen anxiety in slow-COMT individuals by further elevating already-elevated prefrontal dopamine. If anxiety is your primary symptom, start with Selank and evaluate over 2 to 4 weeks before considering whether to add Semax for any remaining cognitive deficit.
Can you take Semax and Selank at the same time?
Pharmacologically possible, but not recommended as a starting strategy. Running both simultaneously makes it impossible to determine which peptide is driving improvement or causing side effects. The standard approach is to start with the peptide matched to your primary symptom, run it for 2 to 4 weeks to establish a clear baseline, and then add the second peptide only if a gap remains. If you eventually run both, an AM/PM split (Selank morning, Semax noon) works better than dosing both simultaneously.
How long does Semax take to work?
Acute effects on focus and mental clarity are typically felt within 30 to 60 minutes of intranasal administration. The BDNF protein elevation that underlies Semax's longer-term cognitive and neuroprotective effects builds over days of consistent dosing and may persist for 24 hours or more after each dose, even though the parent peptide clears plasma in under 5 minutes. Most users report the clearest cognitive effects appearing around day 3 to 7 of a consistent protocol as BDNF expression accumulates.
What is the correct Semax dosage for cognitive enhancement?
Protocols used in research contexts typically range from 200 to 600 micrograms per day intranasally, usually split into morning and midday doses. A common starting point is 200 to 300 micrograms in the morning, with a second dose of 200 micrograms at noon if needed. Cycle length is generally 10 to 30 days, followed by a break of equal or greater duration. No dose-ranging study in healthy humans has established a definitive optimal dose, so starting at the lower end and titrating based on response remains the safest approach.
Is Semax or Selank better for brain fog?
It depends on what is causing the brain fog. Semax is better when the fog is driven by low dopamine tone, low motivation, or poor neuroplasticity with no significant anxiety component. Selank is better when the fog is driven by anxiety interfering with cognition, which is more common than most people realize. If you are unsure, start with Selank. Resolving underlying anxiety almost always produces faster cognitive clarity than adding a nootropic to an anxious brain.
Are Semax and Selank legal in the US in 2026?
As of June 2026, both peptides were removed from the FDA's Category 2 restricted compounding list in April 2026. Neither is DEA-scheduled. A formal Pharmacy Compounding Advisory Committee review is scheduled for July 23-24, 2026, at which point both may be moved to Category 1 status, allowing licensed 503A compounding pharmacies to prepare them under physician prescription. Gray-market research chemical vendors have continued selling both throughout the restriction period, though without manufacturing oversight. Neither peptide is FDA-approved for any US indication.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.